April 10, 2017
Accenture and BioCelerate Collaborate to Advance Biopharmaceutical Innovation Through Increased Insights in Research & Development
NEW YORK; Apr. 10, 2017 – Accenture (NYSE:ACN) today announced it will work with BioCelerate, a subsidiary of TransCelerate BioPharma Inc., a nonprofit focused on improving efficiencies in research and development, to develop a platform enabling its member companies to aggregate and analyze preclinical and clinical information to improve drug development efficiency and bring new medicines to patients faster.
“The ability to collect and leverage large amounts of precompetitive information to create new insights in the R&D process is an important development in the preclinical research space, said Kevin Julian, senior managing director, Accenture Life Sciences North America and Accelerated R&D Services. “We are eager to collaborate with BioCelerate on this critical initiative to further enable the sharing of data to maximize the value of preclinical and clinical research and deliver better patient outcomes.”
The R&D data sharing platform will be built on the Accenture Insights Platform. The Accenture Insights Platform provides a portfolio of advanced analytics capabilities, and an integrated design, build, run environment, to enable the development of industry and function-specific analytics solutions.
The platform will provide participating member companies the ability to assimilate, aggregate, and analyze de-identified preclinical and clinical information, enabling them to draw their respective conclusions from a large data set. The platform will be used initially to support BioCelerate’s first collaborative project, Toxicology & Background Control Data Sharing, to enhance product safety.
”Sharing preclinical data among the BioCelerate member companies can be a powerful tool for improving drug discovery and development. With this initiative, BioCelerate members will be able to make more informed decisions on compound progression based on a better understanding of preclinical safety data,” said Mike Graziano Ph.D., DABT, Vice President of Drug Safety Evaluation at BMS and lead for the BioCelerate initiative.
Dalvir Gill, Ph.D. CEO of TransCelerate BioPharma, Inc. said: “Accenture’s deep expertise in life sciences, digital, analytics, and clinical data-related services will be instrumental in delivering this new platform and builds on the multi-year relationship between Accenture and TransCelerate. All BioCelerate member companies recently signed a collaborative Data Sharing Agreement outlining the guidelines of the data that will be shared across companies. This, along with selecting Accenture to build and host the global data sharing platform, marks another significant milestone in advancing the industry. We are truly excited for the long-term strategic vision of this platform and envisage a future whereby drug developers can connect preclinical, clinical and other data types within the same data sharing platform.”
Following launch of the platform, data from TransCelerate’s Placebo Standard of Care Data Sharing (PSoC) initiative will be migrated, creating the foundation for additional preclinical and clinical data sharing across member companies. The PSoC initiative was established to maximize the value of historic clinical data collected during clinical trials, and was the first cross-therapeutic, multi-sponsor clinical data sharing initiative of its kind designed to improve trial design and safety surveillance.
In October 2015, Accenture was selected by TransCelerate to support its PSoC initiative which has converted data for over 80 trials and more than 67,000 patients across seven therapeutic areas such as Alzheimer’s, cardiovascular disease, and diabetes.
Accenture is a leading global professional services company, providing a broad range of services and solutions in strategy, consulting, digital, technology and operations. Combining unmatched experience and specialized skills across more than 40 industries and all business functions – underpinned by the world’s largest delivery network – Accenture works at the intersection of business and technology to help clients improve their performance and create sustainable value for their stakeholders. With approximately 401,000 people serving clients in more than 120 countries, Accenture drives innovation to improve the way the world works and lives. Visit us at www.accenture.com.
BioCelerate, a subsidiary of TransCelerate BioPharma Inc., focuses on the identification and development of pragmatic and tangible solutions to improve efficiencies in preclinical research, with the end goal of improving overall drug development efficiency to bring new medicines to patients faster. By actively collaborating with participating TransCelerate Member Companies and other industry stakeholders, BioCelerate leverages collective knowledge to tackle areas of common challenge and unmet need in the preclinical research space. The founding Member Companies are Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Novo Nordisk and Shionogi & Co., Ltd.
About TransCelerate BioPharma, Inc.
TransCelerate BioPharma Inc. is a non-profit organization dedicated to improving the health of people around the world by simplifying and accelerating the research and development (R&D) of innovative new therapies. The organizations’ mission is to collaborate across the global biopharmaceutical R&D community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines. TransCelerate evolved from conversations at various forums for executive R&D leadership to discuss current issues facing the industry, and examine solutions for addressing common challenges. The founding member companies are AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, the Roche Group, and Sanofi. Additional members that have joined since the inception of TransCelerate include Allergan, Inc., Amgen, Astellas Pharma Inc., EMD Serono, Inc. (a subsidiary of Merck KGaA, Darmstadt, Germany), Merck & Co., Inc., Novo Nordisk, Shionogi & Co., Ltd. and UCB.
Membership in TransCelerate is open to pharmaceutical and biotechnology companies with Research & Development operations. Executive offices are located in Philadelphia, PA. For more information, please visit http://www.transceleratebiopharmainc.com.
# # #